M. Ladanyi

APOBEC3 mutagenesis drives therapy resistance in breast cancer

This study identifies APOBEC3 mutagenesis as a common driver of therapy resistance in breast cancer, associated with poorer clinical outcomes.

Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy

This study identifies mechanisms of resistance to EZH2 inhibition in SMARCB1-deficient cancers and proposes combination therapies to overcome resistance.

MEK inhibitor resistance in lung cancer cells associated with addiction to sustained ERK suppression

The paper identifies drug addiction to MEK inhibitors in KRAS-mutant lung cancer cells, showing that resistance is linked to ERK suppression and KRAS amplification, suggesting therapeutic strategies involving drug holidays.

Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer

This study identifies the ERK-CBP/p300-ETS axis as promoting lineage transformation between neuroendocrine and non-neuroendocrine lung cancer subtypes through chromatin rewiring.

Establishment of multiple novel patient-derived models of desmoplastic small round cell tumor enabling functional characterization of ERBB pathway signaling and pre-clinical evaluation of a novel targeted therapy approach

This study develops new DSRCT models and shows that targeting the ERBB pathway with EGFR inhibitors reduces tumor growth in preclinical models.

YES1 amplification: a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics

This study identifies YES1 amplification as a novel mechanism of resistance to EGFR inhibitors in lung cancer using transposon mutagenesis and clinical genomic analysis.